We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 20193055]

EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis

This study is being done to find out if starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (time being alive) for patients with your type of cancer.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3071